Mechanisms underlying acquired von Willebrand syndrome associated with an IgM paraprotein

European Journal of Clinical Investigation

Volumn 39, Issue 9, 2009, Pages 833-836

  Mayerhofer, M ^a   Haushofer, A ^b   Kyrle, P A ^a,c   Chott, A ^a   Mullner C ^a   Quehenberger, P ^a   Worel, N ^a   Traby, L ^a   Eichinger, S ^a,c,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Karl Landsteiner Institute for Implementation of Innovative Techniques in Cardiac Surgery   (Austria)

^c Karl Landsteiner Institut für Klinische Thromboseforschung   (Austria)

^d Department of Internal Medicine i ^*  (Austria)

Author keywords

Acquired von Willebrand syndrome; IgM paraprotein; Immunocytoma; Immunoprecipitation

Indexed keywords

FLUDARABINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PARAPROTEIN; RITUXIMAB;

ADULT; ARTICLE; B CELL LYMPHOMA; BLOOD CLOTTING; BONE MARROW BIOPSY; CANCER CELL; CASE REPORT; CYTOPLASM; ELECTROPHORESIS; ENDOTHELIUM CELL; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOMA; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LABORATORY TEST; MALE; MEGAKARYOCYTE; MULTIPLE CYCLE TREATMENT; PARAPROTEINEMIA; PLASMA TRANSFUSION; PLASMACYTOMA; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; RETROPERITONEAL HEMATOMA; VON WILLEBRAND DISEASE;

ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMATOLOGIC TESTS; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PARAPROTEINS; SYNDROME; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 68349125010     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02177.x     Document Type: Article

References (16)

1. Mohri H. Acquired von Willebrand syndrome: features and management. Am J Hematol 2006 81 : 616 23.
2. Federici AB. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol 2006 43 : S48 58.
3. Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000 84 : 345 9.
4. Mohri H. Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management. J Thromb Thrombolysis 2003 15 : 141 9.
5. Tiede A, Priesack J, Werwitzke S, Bohlmann K, Oortwijn B, Lenting P et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost 2008 6 : 569 76.
6. Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia 2003 9 : 303 8.
7. van Genderen PJ, Vink T, Michiels JJ, van 't Veer MB, Sixma JJ, van Vliet HH. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood 1994 84 : 3378 84.
8. Gouault-Heilmann M, Dumont MD, Intrator L, Chenal C, Lejonc JL. Acquired von Willebrand's syndrome with IgM inhibitor against von Willebrand's factor. J Clin Pathol 1979 32 : 1030 5.
9. Brody JI, Haidar ME, Rossman RE. A hemorrhagic syndrome in Waldenstrom's macroglobulinemia secondary to immunoadsorption of factor VIII. Recovery after splenectomy. N Engl J Med 1979 300 : 408 10.
10. Mazurier C, Parquet-Gernez A, Descamps J, Bauters F, Goudemand M. Acquired von Willebrand's syndrome in the course of Waldenstrom's disease. Thromb Haemost 1980 44 : 115 8.
11. Mannucci PM, Lombardi R, Bader R, Horellou MH, Finazzi G, Besana C et al. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood 1984 64 : 614 21.
12. Eikenboom JC, van derMeerFJ, Briet E. Acquired von Willebrand's disease due to excessive fibrinolysis. Br J Haematol 1992 81 : 618 20.
13. Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest 1986 77 : 947 51.
14. Collins P, Budde U, Rand JH, Federici AB, Kessler CM. Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia 2008 14 : S49 55.
15. Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, Budde U et al. Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications. Semin Thromb Hemost 2006 32 : 577 88.
16. Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998 91 : 3623 9.